AcroViz provides the first-to-market microscopic brain axonal integrity assessment service that evaluate axonal degeneration, which can predict brain diseases or mental disorders associated with dementia, such as Alzheimer’s Disease (AD). Clinical data validation has proven statistical significance in predicting the risk and prognosis of dementia, which can serve as a Mild Cognitive Impairment (MCI) image biomarker.
AcroViz’s first product the Axonal Brain Age – Brain Health Report utilizes AcroViz’s core technology, diffusion Magnetic Resonance Imaging and Machine Learning techniques, to evaluate the robustness of whole brain fiber tracts, as well as cognitive function networks including long-term episodic memory & emotion, long-term semantic memory network, long-term semantic memory network, working memory, attention, language, visual and sensorimotor networks.
AcroViz aims to end dementia with advanced neuroimaging technologies, currently working with health-check clinics for preventive healthcare, also hospitals, pharma or medical device companies on various clinical trials to validate the effectiveness of intervention on MCI patients.
Date of establishment：2017/12/5
Fundraising round：A roundWebsite address
AcroViz develops novel imaging biomarkers for brain health, in an effort to prolong human health spa…more...
A medical imaging analysis start-up company that incorporated in December 2017, AcroViz Inc.is found…more...
Contact person：Chen, RuFen
Wen-Yih Isaac Tseng
Cofounder and Chief Medical Officer
Cofounder and Chief Technology Officer
cofounder and president